Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.68 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CTSC | P53634 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | GNPAT | O15228 | 1/20 | 0.53 |
| ▸ | CPA3 | P15088 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048908 | 1.00 | NAALAD2 (0.68) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL6236774 | 1.00 | NAALAD2 (0.68) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL6237394 | 0.97 | NAALAD2 (0.64) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL27652943 | 0.97 | NAALAD2 (0.64) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL30692726 | 0.96 | NAALAD2 (0.67) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL30849218 | 0.95 | NAALAD2 (0.61) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL30123529 | 0.94 | NAALAD2 (0.60) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL22649263 | 0.94 | NAALAD2 (0.60) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL29892222 | 0.93 | NAALAD2 (0.67) | NAALAD2SLC15A1POLBLTA4HGNPAT | |
| SCHEMBL30688832 | 0.93 | NAALAD2 (0.67) | NAALAD2SLC15A1POLBLTA4HGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| CN-119855612-A | Radionuclide coupling medicine, pharmaceutical composition and application thereof | 同宜医药（苏州）有限公司 | 2025-04-18 | — | — | CN | claimed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | claimed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240165006-A1 | DERMATOLOGICAL COMPOSTIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2024-05-23 | — | — | US | claimed |
| WO-2024051794-A1 | RADIONUCLIDE-DRUG CONJUGATE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 同宜医药（苏州）有限公司 | 2024-03-14 | — | — | WO | claimed |
| EP-4313105-A1 | DERMATOLOGICAL COMPOSITIONS AND USE THEREOF | Bone Sci. Bio Ltd. (IL) | 2024-02-07 | — | — | EP | claimed |
| CN-117083075-A | Dermatological composition and use thereof | 邦赛生物有限公司 | 2023-11-17 | — | — | CN | claimed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-114678122-A | Cancer risk prediction method, system, device and medium | 上海市第十人民医院 | 2022-06-28 | — | — | CN | claimed |
| CN-113967247-A | Blood pressure reducing pill and preparation method thereof | 柳春曦 | 2022-01-25 | — | — | CN | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-107236021-A | A kind of synthetic method of polypeptide derivative | 湖北泓肽生物科技有限公司 | 2017-10-10 | — | — | CN | claimed |
| CN-106537145-A | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| CN-1930183-B | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD | 2010-12-29 | — | — | CN | claimed |
| CN-1930183-A | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD (CN) | 2007-03-14 | — | — | CN | claimed |
| WO-2005016959-A1 | BIOLOGICALLY ACTIVE PEPTIDES COMPRISING PHENYLALANYL-GLUTAMATE (FE) AND PHENYLALANYL-GLUTAMYL-GLUTAMATE (FEE) | PEPHARM R & D LIMITED (CN) | 2005-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | NAALAD2 1172/4885SLC15A1 172/4885POLB 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.